Gilead Sciences, Inc. (NASDAQ:GILD) Shares Purchased by Aprio Wealth Management LLC

Aprio Wealth Management LLC boosted its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 124.7% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 7,766 shares of the biopharmaceutical company’s stock after purchasing an additional 4,310 shares during the period. Aprio Wealth Management LLC’s holdings in Gilead Sciences were worth $717,000 at the end of the most recent quarter.

Other institutional investors have also recently added to or reduced their stakes in the company. nVerses Capital LLC acquired a new stake in Gilead Sciences in the 3rd quarter valued at approximately $25,000. Valued Wealth Advisors LLC grew its stake in shares of Gilead Sciences by 101.9% in the third quarter. Valued Wealth Advisors LLC now owns 319 shares of the biopharmaceutical company’s stock worth $27,000 after acquiring an additional 161 shares in the last quarter. Cedar Wealth Management LLC grew its stake in shares of Gilead Sciences by 51.6% in the second quarter. Cedar Wealth Management LLC now owns 470 shares of the biopharmaceutical company’s stock worth $32,000 after acquiring an additional 160 shares in the last quarter. Strategic Investment Solutions Inc. IL acquired a new position in shares of Gilead Sciences in the second quarter worth $33,000. Finally, Quarry LP acquired a new position in shares of Gilead Sciences in the second quarter worth $43,000. Institutional investors and hedge funds own 83.67% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have commented on GILD shares. Leerink Partnrs upgraded shares of Gilead Sciences from a “hold” rating to a “strong-buy” rating in a research note on Monday, October 21st. Royal Bank of Canada restated a “sector perform” rating and issued a $84.00 price target on shares of Gilead Sciences in a research note on Wednesday, December 11th. Oppenheimer boosted their target price on shares of Gilead Sciences from $105.00 to $115.00 and gave the stock an “outperform” rating in a research note on Tuesday, December 10th. Cantor Fitzgerald reiterated a “neutral” rating and set a $80.00 target price on shares of Gilead Sciences in a research note on Wednesday, December 11th. Finally, Daiwa America upgraded shares of Gilead Sciences to a “hold” rating in a research note on Monday, November 18th. Eleven investment analysts have rated the stock with a hold rating, thirteen have issued a buy rating and four have issued a strong buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $97.96.

Insider Buying and Selling

In other news, insider Merdad Parsey sold 25,590 shares of the stock in a transaction that occurred on Wednesday, November 6th. The shares were sold at an average price of $91.50, for a total value of $2,341,485.00. Following the sale, the insider now directly owns 99,599 shares in the company, valued at $9,113,308.50. This represents a 20.44 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Andrew D. Dickinson sold 8,500 shares of the stock in a transaction that occurred on Monday, December 16th. The shares were sold at an average price of $91.96, for a total transaction of $781,660.00. Following the completion of the sale, the chief financial officer now owns 132,373 shares in the company, valued at $12,173,021.08. This represents a 6.03 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 453,734 shares of company stock valued at $41,902,086 over the last ninety days. Corporate insiders own 0.16% of the company’s stock.

Gilead Sciences Price Performance

Shares of NASDAQ:GILD opened at $89.88 on Monday. The company has a 50-day simple moving average of $91.94 and a 200-day simple moving average of $83.39. Gilead Sciences, Inc. has a one year low of $62.07 and a one year high of $98.90. The company has a debt-to-equity ratio of 1.24, a quick ratio of 1.10 and a current ratio of 1.26. The stock has a market capitalization of $112.01 billion, a price-to-earnings ratio of 998.67, a PEG ratio of 2.24 and a beta of 0.18.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings results on Wednesday, November 6th. The biopharmaceutical company reported $2.02 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.58 by $0.44. The firm had revenue of $7.55 billion during the quarter, compared to analysts’ expectations of $7.01 billion. Gilead Sciences had a net margin of 0.45% and a return on equity of 29.00%. The firm’s revenue for the quarter was up 7.0% on a year-over-year basis. During the same period in the prior year, the company posted $2.29 earnings per share. On average, analysts predict that Gilead Sciences, Inc. will post 4.36 EPS for the current year.

Gilead Sciences Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Monday, December 30th. Investors of record on Friday, December 13th were issued a dividend of $0.77 per share. The ex-dividend date of this dividend was Friday, December 13th. This represents a $3.08 annualized dividend and a yield of 3.43%. Gilead Sciences’s dividend payout ratio is currently 3,422.22%.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.